Published Studies Related to Atrovent (Ipratropium)
The effect of administrative cessation of the use of ipratropium bromide in the treatment of acute asthma attacks in the emergency department. [2011.12]
Inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. [2011.04]
BACKGROUND: The combination of inhaled beta(2) agonists and anticholinergics is recommended for children with acute asthma, although there are few randomized controlled trials. The aim of the study was to determine whether salbutamol plus ipratropium bromide improves oxygenation and lung function and reduces the frequency of hospitalization in children with asthma crises... CONCLUSIONS: Salbutamol plus ipratropium bromide improves lung function in asthmatic children with moderate to severe asthma crises, independently of age. The effect is greater in children with severe crises, with a substantial reduction in the need for hospitalization.
Levalbuterol versuss levalbuterol plus ipratropium in the treatment of severe acute asthma. [2010.12]
BACKGROUND: The National Asthma Education and Prevention Program (NAEPP) Expert Panel Report 3 guidelines advise the addition of ipratropium bromide to short-acting beta-agonist therapy for the treatment of patients with severe acute asthma exacerbation... CONCLUSION: We were unable to demonstrate superiority of adding ipratropium to levalbuterol in alleviating obstruction as measured by FEV or in decreasing the need for hospitalization among adult patients presenting to the ED with acute severe asthma exacerbation.
Functional response to inhaled salbutamol and/or ipratropium bromide in Ascaris suum-sensitised cats with allergen-induced bronchospasms. [2010.10]
Knowledge about the use of inhaled bronchodilators in cats with so-called 'feline asthma' is limited and relies on the experience of clinicians treating these patients. A randomised controlled four-way crossover study was therefore designed to compare the effects of salbutamol (SAL, 100 mug), ipratropium bromide (IB, 20 mug) and a combination of both (SAL/IB, 100 mug/20 mug), delivered through a pressurised metered-dose inhaler (pMDI) connected to a spacing chamber, on allergen-induced bronchospasms in five Ascaris suum (AS)-sensitised cats...
Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI. [2010.08]
We compared the efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler, a novel propellant-free inhaler, versus chlorofluorocarbon (CFC)-metered dose inhaler (MDI) and ipratropium Respimat inhaler in patients with COPD. This was a multinational, randomized, double-blind, double-dummy, 12-week, parallel-group, active-controlled study...
Clinical Trials Related to Atrovent (Ipratropium)
A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium [Recruiting]
The objective of this study is to assess the daily variation in bronchodilator response to
an inhaled short acting beta2-agonist (albuterol/salbutamol) and an inhaled short acting
anticholinergic (ipratropium) individually and when used in combination in subjects with
Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva [Completed]
To evalute acute effect of single dose of ipratropium (Atrovent) or fenoterol (Berotec) in
comparison to placebo when given to COPD patients on pharmacodynamic steady state of
Effect of Ipratropium on Acute Bronchitis in Subjects Without Underlying Lung Disease [Completed]
ABSTRACT CONTEXT: Inappropriate antibiotic prescriptions for acute bronchitis is a major
public health concern because of antibiotic resistance. Effective therapies for managing the
symptoms of acute bronchitis are lacking, however.
OBJECTIVE: Determine if patients with acute bronchitis have better symptom control when
treated with inhaled ipratropium.
DESIGN, SETTING, PARTICIPANTS: COUGH STOP was a randomized, double blind, placebo controlled
trial comparing ipratropium with placebo in acute bronchitis. Subjects were referred by
their primary care provider or from urgent care clinics at a single institution. Subjects
had been diagnosed with acute bronchitis and had no significant co-morbidities.
INTERVENTION: Subjects received ipratropium or placebo inhalers, administering 2 puffs four
times daily. A structured telephone interview took place 2, 4, and 8 days after enrollment.
Medical records were reviewed at 60 days.
OUTCOME: The primary endpoint was improvement in cough symptomology; secondary endpoints
included subsequent antibiotic prescriptions and â€śwell being. â€ť RESULTS: The ipratropium arm
improved significantly (better: 57. 6% day-2, 68. 3% day-4, 91. 9% day-8; c2 (1) = 21. 24, p <
.01) across the 8 days of the telephone survey. This score improved over the same time
period in the placebo arm, however the change was smaller and the difference was not
significant (better: 64. 8% day-2, 74. 6% day-4, 79. 7% day-8; c2 (1) = 4. 69, p =.321). More
than twice as many subjects in the placebo arm received subsequent antibiotic prescriptions
compared to the ipratropium arm (12 vs. 5 respectively), this trend did not meet the
threshold of significance (c2 (1) = 2. 84, p =.076).
CONCLUSION: Patients with acute bronchitis who are otherwise healthy have a more rapid
improvement in their cough symptom score when they are treated with ipratropium, and may be
at decreased risk of unnecessary antibiotic exposure.
Tiotropium Inhalation Capsules and Atrovent MDI Comparison Trial in Taiwan [Completed]
The objective of this study is to compare the bronchodilator efficacy and safety of
tiotropium inhalation capsules (18 mcg once daily) and Atrovent MDI (2 puffs of 20 mcg
q. i.d.) in patients with chronic obstructive pulmonary disease (COPD)
A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation [Recruiting]
This is a double blind, controlled clinical trail testing whether three doses of 1. 25 mg of
nebulized levalbuterol in combination with three doses of 0. 5mg of nebulized ipratropium
will lead to greater bronchodilation than that achieved by three doses of nebulized 1. 25 mg
of levalbuterol alone every 20 minutes.
The primary hypothesis of this study is that three doses of 1. 25 mg of nebulized
levalbuterol in combination with three doses of 0. 5mg of nebulized ipratropium will lead to
greater bronchodilation than that achieved by three doses of nebulized 1. 25 mg of
levalbuterol alone every 20 minutes. The secondary hypothesis is that the treatment
combination of levalbuterol and ipratropium will lead to fewer hospitalizations than
levalbuterol alone in patients with acute asthma exacerbation. Other secondary objectives
include (1) evaluating the relationship between baseline (S)- albuterol levels and (R)-
albuterol levels on presentation and FEV1, (2) the relationship between baseline (S)-
albuterol levels and (R)- albuterol levels on presentation and change in FEV1,(3) time to
event analysis for an improvement of 15%, 20%, 30%, 40%, and 50% in FEV1 from initial
presentation value, (4) analysis of FEV1 at discharge.
Reports of Suspected Atrovent (Ipratropium) Side Effects
Confusional State (6),
Renal Failure (5),
Hyponatraemia (4), more >>